CNCR vs. BBP

Last updated Apr 3, 2026

Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and Virtus LifeSci Biotech Products ETF (BBP).

CNCR and BBP are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. BBP is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Products Index. It was launched on Dec 17, 2014. Both CNCR and BBP are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

CNCR vs. BBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Virtus LifeSci Biotech Products ETF (BBP). The values are adjusted to include any dividend payments, if applicable.

CNCR vs. BBP - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
BBP Virtus LifeSci Biotech Products ETF	2.06%

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

BBP

• 1D: -0.03%
• 1M: 2.58%
• YTD: 4.74%
• 6M: 17.29%
• 1Y: 43.95%
• 3Y*: 19.26%
• 5Y*: 9.54%
• 10Y*: 12.76%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. BBP - Expense Ratio Comparison

Both CNCR and BBP have an expense ratio of 0.79%.

CNCR

Loncar Cancer Immunotherapy ETF

BBP

Virtus LifeSci Biotech Products ETF

Return for Risk

CNCR vs. BBP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBP

BBP Risk / Return Rank: 83
BBP Sharpe Ratio Rank: 82
BBP Sortino Ratio Rank: 83
BBP Omega Ratio Rank: 73
BBP Calmar Ratio Rank: 90
BBP Martin Ratio Rank: 89

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. BBP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Virtus LifeSci Biotech Products ETF (BBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	BBP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.65	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.37	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.47	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.39	—

Dividends

CNCR vs. BBP - Dividend Comparison

Neither CNCR nor BBP has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
BBP Virtus LifeSci Biotech Products ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.00%	1.29%

Drawdowns

CNCR vs. BBP - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum BBP drawdown of -44.32%. Use the drawdown chart below to compare losses from any high point for CNCR and BBP.

Drawdown Indicators

	CNCR	BBP	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-44.32%	+44.32%
Max Drawdown (1Y) Largest decline over 1 year	—	-11.09%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-38.28%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-44.32%	—
Current Drawdown Current decline from peak	0.00%	-3.15%	+3.15%
Average Drawdown Average peak-to-trough decline	0.00%	-12.16%	+12.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.63%	—

Volatility

Volatility by Period

	CNCR	BBP	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	10.34%	—
Volatility (6M) Calculated over the trailing 6-month period	—	17.98%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	26.82%	-26.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	26.21%	-26.21%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	27.50%	-27.50%